McIlrath & Eck’s Vertex Pharmaceuticals VRTX Stock Holding History

McIlrath & Eck’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-397	Closed	-$185K	–	1032
2024 Q3	$185K	Hold	397	–	–	0.02%	127
2024 Q2	$186K	Hold	397	–	–	0.03%	123
2024 Q1	$166K	Buy	397 +91	+30%	+$38.5K	0.03%	127
2023 Q4	$125K	Sell	306 -91	-23%	-$33.6K	0.02%	148
2023 Q3	$138K	Hold	397	–	–	0.03%	136
2023 Q2	$140K	Sell	397 -9	-2%	-$3.03K	0.03%	131
2023 Q1	$128K	Buy	406 +9	+2%	+$2.7K	0.03%	134
2022 Q4	$115K	Hold	397	–	–	0.03%	136
2022 Q3	$115K	Hold	397	–	–	0.03%	132
2022 Q2	$112K	Hold	397	–	–	0.03%	122
2022 Q1	$104K	Hold	397	–	–	0.03%	134
2021 Q4	$87K	Hold	397	–	–	0.02%	165
2021 Q3	$72K	Sell	397 -215	-35%	-$42K	0.02%	183
2021 Q2	$123K	Buy	612 +299	+96%	+$62.5K	0.04%	129
2021 Q1	$67K	Buy	313 +306	+4,371%	+$67.2K	0.02%	167
2020 Q4	$2K	Hold	7	–	–	﹤0.01%	634
2020 Q3	$2K	Hold	7	–	–	﹤0.01%	612
2020 Q2	$2K	Hold	7	–	–	﹤0.01%	611
2020 Q1	$2K	Sell	7 -4	-36%	-$918	﹤0.01%	588
2019 Q4	$2K	Buy	11 +4	+57%	+$810	﹤0.01%	580
2019 Q3	$1K	Hold	7	–	–	﹤0.01%	609
2019 Q2	$1K	Hold	7	–	–	﹤0.01%	601
2019 Q1	$1K	Hold	7	–	–	﹤0.01%	601
2018 Q4	$1K	Hold	7	–	–	﹤0.01%	520
2018 Q3	$1K	Hold	7	–	–	﹤0.01%	516
2018 Q2	$1K	Hold	7	–	–	﹤0.01%	497
2018 Q1	$1K	Hold	7	–	–	﹤0.01%	461
2017 Q4	$1K	Buy	+7	New	+$1.04K	﹤0.01%	501

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

McIlrath & Eck's VRTX Position: Q4 2024 in Review

McIlrath & Eck sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 397 shares — an estimated $185K sold.

McIlrath & Eck first reported a position in VRTX in Q4 2017 and held it in 28 quarters. The position peaked at $186K in Q2 2024. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

McIlrath & Eck reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
McIlrath & Eck sold 397 Vertex Pharmaceuticals shares in Q4 2024, an estimated $185K.
McIlrath & Eck first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 28 quarters.
McIlrath & Eck's Vertex Pharmaceuticals position peaked at $186K in Q2 2024.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on McIlrath & Eck's 13F filing for Q4 2024, filed 18 Feb 2025.